App-Quantinova.ai

TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia

Scott R. Solomon - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Mycophenolate mofetil

Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Ryan Urak - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

6-mercaptopurine

Combined Inhibition of MCL1 By AZD5991 and BCL2/Bclxl By AZD4320 As Promising Strategies to Overcome Acute Leukemia Tumor Burden and Niche Chemoresistance

Maura Lima Pereira Bueno - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Nitric oxide

HCK Inhibition Displays Antineoplastic Activity on Acute Leukemia and Promotes Immune Regulation of the Bone Marrow Tumor Microenvironment

Fernanda Marconi Roversi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia

Karina Thiel-Klare - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Trametinib

Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia

Caner Saygin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Navitoclax

Identification of a Novel Nucleoside Prodrug with Preferential Activity in Lymphoma and Leukemia Subtypes

Marissa L Calbert - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Decitabine

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Vibhu Agarwal - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia

Evelyn Kendall Williams - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Daunorubicin

Financial Coping Strategies and Financial Assistance Following a Pediatric Hematologic Malignancy

Jackie Jin Lin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Alex Hoover - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)

Mayur Narkhede - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Assessing the Safety of Discharging Patients Receiving High-Dose Methotrexate with Levels Greater Than 0.1 Umol/L

Elaine Xiang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

sodium bicarbonate

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Nosha Farhadfar - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

Overall Survival of Adult Acute Lymphoblastic Leukemia (ALL) Patients By Facility Volume and Type: A National Cancer Database Report

Kaitlyn C Dykes - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Patient Characteristics, Treatment Patterns, and Cost Variations By Race/Ethnicity Among Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia Initiating First Salvage Therapy

Megan C Braunlin - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

Health Care Resource Utilization and Costs Among Patients with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Blinatumomab during First Salvage in Relapse/Refractory

Alexander Russell-Smith - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

COVID-19 Vaccination Outcomes in Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia

Rebecca S Parker - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute lymphoblastic leukemia

N/A

Filters

2187 Abstracts